At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Avastin +2 moredrug
Likely dose
Avastin 1.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-Month, Single Site, Masked, Randomized,Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion
In Brief
A Phase 4 clinical trial evaluating Avastin and Osurdex for Retinal Vein Occlusions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Comparative study to see if treating with Osurdex in addition to Avastin in patients with retinal vein occlusions helps increased visual acuity outcomes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusions
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMar 2010
Primary CompletionOct 2011
TodayJul 2026
First PostedMar 12, 2010
Enrollment StartMar 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 16.3 years ago
Interventions
Avastindrug
1.25mg intravitreally
Osurdexdrug
0.7mg intravitreally
Avastindrug
1.25mg intravitreally